Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Peptech Announces Director Retirements

Peptech Announces Director Retirements

Peptech Limited (ASX:PTD, AIM: PTDx) today announced as part of its merger agreement with EvoGenix that Martin Kriewaldt and Till Medinger will retire as directors of the company, effective 28 August 2007.

Mel Bridges, Chairman of Peptech thanked both directors for the services provided to the company, commenting:

"Till has been a director of the company since 1997. He has been a consistent contributor at board level, with his international industry knowledge being particularly valuable. As Peptech's alternate director on the Domantis board, Till was instrumental in Peptech's continuing participation in Domantis and the very successful realisation of that investment.

"Since joining the Peptech Board in October 2003, Martin's litigation experience has been particularly invaluable in the disputes Peptech had with Centocor and Abbott. More recently he has used his skills in guiding Peptech through its merger and acquisition activity, spending considerable time on due diligence activities. "On behalf of the entire Peptech board I sincerely thank both these directors for their commitment to Peptech," he added.

Effective from 28 August 2007, Chris Harris and Robin Beaumont, formerly directors of EvoGenix Limited, will join the Peptech Board.

About Peptech:

Peptech Limited is a biotechnology company dedicated to developing and providing antibody and peptide-based human therapeutic products for the treatment of cancer and inflammatory diseases.

The Company has tapped its unique antibody technologies and revenues generated from its pioneering anti-TNF patents to build a range of therapeutic assets to address large and clinically validated markets.

Peptech is transitioning to a mid-stage development company as several products move from pre-clinical stages into human trials, starting with the Company's lead compound, PN0621, a differentiated anti-TNF domain antibody construct.

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Tax: GST Threshold For Online Purchases Won't Lower Before 2018

The government wants to lower the threshold on online purchases which qualify for GST from mid-2018, but says more work is needed and there will be no change without public consultation. More>>

ALSO:

North Canterbury: Government Extends Drought Classification

The government has extended a drought classification for the eastern South Island until the end of the year, meaning the area will have officially been in drought for almost two years, the longest period for such a category. More>>

ALSO:

Negotiations Fail: Christchurch Convention Centre Build To Proceed Without PCNZ

After protracted negotiations, the government has ditched the construction consortium it picked to build Christchurch's replacement convention centre, which it now anticipates delivering at least two years behind the original schedule. More>>

ALSO:

Ruataniwha: Greenpeace Launches Legal Challenge Against $1b Dam Plan

Greenpeace NZ is launching a legal challenge against a controversial plan to build a dam that’s set to cost close to $1 billion and will pollute a region’s rivers. More>>

ALSO:

Inequality: Top 10% Of Housholds Have Half Of Total Net Worth

The average New Zealand household was worth $289,000 in the year to June 2015, Statistics New Zealand said today. However wealth was not evenly distributed, with the top 10 percent accounting for around half of total wealth. In contrast, the bottom 40 percent held 3 percent of total wealth. More>>

ALSO:

What Winter? Temperature Records Set For June 20-22

The days around the winter soltice produced a number of notably warm tempertaures. More>>

Conservation Deal: New Kākāpō Recovery Partnership Welcomed

Conservation Minister Maggie Barry says the new kakapo recovery partnership between DOC and Meridian Energy is great news for efforts to save one of New Zealand’s most beloved birds. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news